oral glp 1 agonist Orforglipron, an Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Oral GLP-1-Based Therapeutics in the
Description
All covariates were assessed at baseline (index date) and did not vary over time

If you haven't seen meaningful weight loss or lipid changes after three months of consistent semaglutide use, your doctor may increase your dose or explore additional factors like diet quality or medication timing
[DOI] [PMC free article] [PubMed] [Google Scholar] 246.Jeruszka-Bielak M., Kollajtis-Dolowy A., Santoro A., Ostan R., Berendsen A.A.M., Jennings A., Meunier N., Marseglia A., Caumon E., Gillings R., et al

Which GLP-1 is right for me

Comparing it to someone else is misleading and often leads to inappropriate dose adjustments
Grech O, Mollan SP, Wakerley BR, Alimajstorovic Z, Lavery GG, Sinclair AJ
